The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCAR-T 2019 | Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
John Gribben, MD, DSc , FRCPath, FMed Sci, Barts Cancer Institute, London, UK, is joined by Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, to share their highlights from day 2 of the 1st International Workshop on CAR-T (iwCAR-T), held in Miami, FL. The speakers discuss difficulties in targeting acute myeloid leukemia (AML), CAR T-cell therapy in multiple myeloma and clinical trial regulations in China. Allogeneic CAR-Ts are also touched upon.
